Clinical Cancer Research · 2008 · 43 citations · 39 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunogeneticsInflammationCytokine BiologyCytokine Gene PolymorphismImmunogenomicsInflammatory SignalingInterleukin Gene VariantsAnticancer ChemotherapyCytokine Receptor PolymorphismsInflammatory Gene PolymorphismsInflammatory Mediator PolymorphismsInterleukin Gene VariationInterleukin-10 Gene VariantsTreatment Response Biomarkers
PURPOSE: Current chemotherapy can achieve high response rates in aggressive non-Hodgkin's lymphoma (NHL), but the factors that influence regression and survival remain unknown. The present exploratory study tested the hypothesis whether interleukin-10 (IL-10) polymorphisms predict clinical outcome, leukocytopenia, or infectivity during therapy. IL-10 was chosen because immune alterations are a major risk factor for NHL, and IL-10 is a cytokine involved in inflammatory processes associated with clinical outcome. EXPERIMENTAL DESIGN: Five hundred patients with aggressive NHL treated with CHOP/CHOEP were analyzed for IL-10 gene polymorphisms, including distal loci -7400InDel, -6752AT (rs6676671), and -6208CG (rs10494879) in comparison with proximal loci -3538AT (rs1800890), -1087AG (rs1800896), and -597AC (rs1800872) according to the incidence and outcome of the lymphoma. RESULTS: No differences in allele frequencies or haplotypes were found comparing a cohort of patients with aggressive NHL/diffuse large B-cell lymphoma with a healthy control group. Patients with aggressive NHL characterized by IL-10(-7400DelDel) had shorter overall survival periods compared with the other genotypes (P = 0.004). The 3-year rate is 43.4% for IL-10(-7400DelDel) and 73.4% for IL-10(-7400InIn) and IL-10(-7400InDel) together. A significant increased risk for event-free survival is found for carriers of the genotype IL-10(-6752TT-6208CC-3538AA) (P = 0.047). Multivariate analysis of IL-10(-7400) gene variation in relation to overall survival adjusted to international prognostic index revealed a relative risk of 1.9 for carriers of IL-10(-7400DelDel) (P = 0.037). No associations were found analyzing diffuse large B-cell lymphoma patients separately. CONCLUSION: Our results indicate that IL-10 gene variations could be associated to the clinical course of aggressive NHL, which points out the importance of host factors and respective genetic elements for treatment response.
39
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations
AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER
David M. Turner, Denise Williams, David Sankaran et al. · European Journal of Immunogenetics · 1997 · 1.7K citations
Life Sciences, Genetics, Immunology +14
Andreas Rosenwald, George W. Wright, Karen Leroy et al. · The Journal of Experimental Medicine · 2003 · 1.1K citations · Full text
Medicine, Hematology, Oncology +14
Genetic influence on cytokine production and fatal meningococcal disease
Rudi GJ Westendorp, Jan A. M. Langermans, T. Huizinga et al. · The Lancet · 1997 · 807 citations